SubsidieMeestersCommercialising a smart cardiac implant platform for the treatment of chronic cardiovascular disease
AuriGen's platform aims to reduce chronic cardiac disease deaths and costs in Europe by providing advanced, multi-functional cardiac devices for effective, minimally invasive patient treatment.
Projectdetails
Introduction
Every year, chronic cardiac disease causes 3.9 million deaths in Europe, which translates to a death every 8 seconds. Overall, chronic cardiac disease is estimated to cost the EU 210 billion EUR per year in direct healthcare costs. All chronic cardiac disease patients are at high risk of stroke, atrial fibrillation, and/or heart failure.
AuriGen Platform Overview
The AuriGen platform is singularly focused on addressing the leading causes of death in the developed world: Cardiovascular Diseases. It aims to allow more complex patients to be treated more effectively and at a lower cost per patient.
Device Features
AuriGen's platform consists of four devices built around our custom cardiac implant. We can add synergistic modules such as:
- Cardiac monitoring
- Ablation
- Both modules
This creates devices that are much more than the sum of their parts, which is our key Unique Selling Proposition (USP).
Patient Management
AuriGen enables the efficient and effective management of the most expensive and sub-optimally treated patients through a single, safe, fast, minimally invasive procedure.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.999.999 |
Tijdlijn
| Startdatum | 1-6-2023 |
| Einddatum | 30-6-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- AURIGEN MEDICAL LIMITEDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoringThe Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations. | EIC Accelerator | € 2.299.633 | 2023 | Details |
The first heart failure therapy management point-of-care device with multiplex and multimodal sensorCardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%. | EIC Accelerator | € 2.499.999 | 2025 | Details |
Development and clinical evaluation of an end-to-end Heart Failure management solution powered by predictive AIImplicity is developing an AI-driven platform to predict heart failure events using cardiac device data, enhancing patient care and reducing hospitalizations through tailored insights and management tools. | EIC Accelerator | € 2.488.359 | 2025 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring
The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.
The first heart failure therapy management point-of-care device with multiplex and multimodal sensor
CardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%.
Development and clinical evaluation of an end-to-end Heart Failure management solution powered by predictive AI
Implicity is developing an AI-driven platform to predict heart failure events using cardiac device data, enhancing patient care and reducing hospitalizations through tailored insights and management tools.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Connected Cardiac CareHet Connected Cardiac Care project ontwikkelt een hoogtechnologisch platform voor thuiszorg van hartpatiënten, gericht op vroegtijdige signalering van ziekteverschijnselen via mobiele gezondheidsmeters. | Mkb-innovati... | € 146.431 | 2016 | Details |
Implantable sensors and ultrasonic data link with triggered bioresorption for next-gen wireless cardiac monitoringThe 2ND-CHANCE project aims to develop bioresorbable implants for continuous cardiac monitoring post-surgery, reducing rehospitalization risks and eliminating the need for removal surgery. | ERC Starting... | € 2.500.000 | 2022 | Details |
Speckle Technology and Digital Biomarkers of Microvascular Function for Monitoring Cardiovascular DiseasesThe project aims to develop innovative monitoring instruments for early detection of cardiovascular diseases, integrating advanced technologies to reduce healthcare burdens and costs in the EU. | EIC Pathfinder | € 3.979.006 | 2023 | Details |
Novel microsensing platform for remote patient monitoringThe FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users. | EIC Transition | € 2.499.051 | 2023 | Details |
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Connected Cardiac Care
Het Connected Cardiac Care project ontwikkelt een hoogtechnologisch platform voor thuiszorg van hartpatiënten, gericht op vroegtijdige signalering van ziekteverschijnselen via mobiele gezondheidsmeters.
Implantable sensors and ultrasonic data link with triggered bioresorption for next-gen wireless cardiac monitoring
The 2ND-CHANCE project aims to develop bioresorbable implants for continuous cardiac monitoring post-surgery, reducing rehospitalization risks and eliminating the need for removal surgery.
Speckle Technology and Digital Biomarkers of Microvascular Function for Monitoring Cardiovascular Diseases
The project aims to develop innovative monitoring instruments for early detection of cardiovascular diseases, integrating advanced technologies to reduce healthcare burdens and costs in the EU.
Novel microsensing platform for remote patient monitoring
The FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users.
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.